Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 1422 results for social care

  1. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

  2. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  3. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

  4. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

  5. Supporting the health and care system to implement virtual wards

    Virtual wards (also known as hospital at home) provide hospital level care at home. People on a virtual ward are cared for by a...

  6. NICE International

    An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing

  7. Benefits of implementing NICE guidance

    NICE guidance on the benefits of implementing

  8. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development [GID-TA11561] Expected publication date: 13 August 2025

  9. Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]

    In development [GID-TA11630] Expected publication date: 11 September 2025

  10. Our research work

    NICE's research work and partnerships with researchers, funders, charities and policy organisations.

  11. DCVax-L for treating glioblastoma [ID836]

    In development [GID-TA10143] Expected publication date: TBC

  12. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

  13. Mental wellbeing at work (NG212)

    This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.